Alpha 2.0
Login Register
» Authors » Lesley McFarlane

Lesley McFarlane

Explore the profile of Lesley McFarlane including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 102
Followers 0
Related Specialties
Pharmacology
Pulmonary Medicine
General Medicine
Top 10 Co-Authors
Brian J Lipworth
Arun Nair
Daniel Menzies
Martyn Barnes
Jack Welch
Gareth J Magee
Patricia Burns
Dougal S Hargreaves
Ted Baker
Linda C Orr
Published In
Br J Clin Pharmacol
Chest
Pulm Pharmacol Ther
JAMA
Arch Dis Child
Affiliations
Soon will be listed here.
Recent Articles
1.
Measuring and improving the quality of NHS care for children and young people
Hargreaves D, Lemer C, Ewing C, Cornish J, Baker T, Toma K, et al.
Arch Dis Child . 2018 May; 104(7):618-621. PMID: 29720493
No abstract available.
2.
A novel breath-actuated integrated vortex spacer device increases relative lung bioavailability of fluticasone/salmeterol in combination
Nair A, Clearie K, Menzies D, Meldrum K, McFarlane L, Lipworth B
Pulm Pharmacol Ther . 2009 Jun; 22(4):305-10. PMID: 19489129
Background: Spacer devices facilitate respirable drug delivery. A novel breath-actuated antistatic spacer with integrated vortex chamber (Synchro-Breathe) device has been developed, which is compact,portable and user friendly as compared to...
3.
In vivo comparison of the relative systemic bioavailability of fluticasone propionate from three anti-static spacers and a metered dose inhaler
Nair A, Menzies D, Hopkinson P, McFarlane L, Lipworth B
Br J Clin Pharmacol . 2009 Feb; 67(2):191-8. PMID: 19220273
What Is Already Known About This Subject: Conventional spacers help overcome problems with co-ordination and may improve lung deposition and decrease oropharyngeal impaction. Antistatic spacers eliminate electrostatic charge and may...
4.
Respirable dose delivery of fluticasone propionate from a small valved holding chamber, a compact breath actuated integrated vortex device and a metered dose inhaler
Nair A, Menzies D, Barnes M, Burns P, McFarlane L, Lipworth B
Br J Clin Pharmacol . 2008 Mar; 66(1):20-6. PMID: 18341676
Aims: To compare the respirable dose delivery of the hydrofluroalkane fluticasone propionate (HFA-FP) via an optimally prepared Aerochamber Plus spacer (AP), via a Synchro-Breathe (SB) device, and pMDI Evohaler (EH)....
5.
Respiratory symptoms, pulmonary function, and markers of inflammation among bar workers before and after a legislative ban on smoking in public places
Menzies D, Nair A, Williamson P, Schembri S, Al-Khairalla M, Barnes M, et al.
JAMA . 2006 Oct; 296(14):1742-8. PMID: 17032987
Context: Scotland prohibited smoking in confined public places on March 26, 2006. Objective: To investigate the association of smoke-free legislation with symptoms, pulmonary function, and markers of inflammation of bar...
6.
Therapeutic ratio of hydrofluoroalkane and chlorofluorocarbon formulations of fluticasone propionate
Fowler S, Orr L, Sims E, Wilson A, Currie G, McFarlane L, et al.
Chest . 2002 Aug; 122(2):618-23. PMID: 12171841
Objectives: To compare the therapeutic ratio of chlorofluorocarbon (CFC) and hydrofluoroalkane-134a (HFA) formulations of fluticasone propionate (FP). Methods: We performed a randomized, placebo-controlled, crossover study comparing 6 weeks of treatment...